{"schema_version":"secwatch.filing_event.v1","accession":"0001650664-24-000006","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.979972+00:00","generated_at":"2026-06-05T08:59:39.781148+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Editas reports Q4 net loss of $18.9M; Vertex license deal provides cash runway into 2026","bullets":["Q4 net loss $18.9M ($0.23 per share) vs $60.7M ($0.88) in Q4 2022; revenue boosted by Vertex license.","Cash $427.1M as of Dec 31, 2023; with Vertex license payments, runway expected into 2026.","FDA aligns that RUBY trial is single Phase 1/2/3 to support BLA; adolescent cohort enrollment initiated.","Entered license agreement with Vertex for Cas9 for ex vivo SCD/beta thal; $50M contingent upfront plus annual fees."],"urls":{"canonical":"https://secwatch.observer/filing/0001650664-24-000006","json":"https://secwatch.observer/filing/0001650664-24-000006.json","markdown":"https://secwatch.observer/filing/0001650664-24-000006.md","text":"https://secwatch.observer/filing/0001650664-24-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000006/0001650664-24-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000006/edit-20240228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T08:59:39.781148+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}